WARSAW, Ind., July 30 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. , an independent provider of products to the global orthopedic device industry and other medical markets, announced today a manufacturing and supply agreement with MAKO Surgical Corp., an orthopedic surgical solutions company. Under the agreement, Symmetry Medical will supply MAKO with future implants, instruments and associated products designed to be used in delivering MAKO’s MAKOplasty(TM) therapy.
MAKOplasty(TM) is an innovative, restorative surgical solution that enables orthopedic surgeons to reproducibly and precisely treat patient- specific early to mid stage osteoarthritic knee disease. MAKOplasty is performed using MAKO’s proprietary, FDA-cleared Haptic Guidance System(TM), a surgeon-interactive haptic robotic platform that utilizes patient-specific visualization to prepare the knee joint for insertion of MAKO’s resurfacing implants through a keyhole, bone-preserving and tissue-sparing incision. MAKOplasty is designed for the large and growing, yet underserved population of patients with early to mid stage osteoarthritic knee disease who desire a restoration of lifestyle, pain reduction and a rapid recovery.
“As MAKO’s lead development and manufacturing provider, Symmetry will enhance MAKO’s ability to bring its innovative technologies to the market more widely and rapidly, and enable the company to meet the growing demand for its systems,” stated Brian Moore, President and Chief Executive Officer of Symmetry Medical. “This agreement keeps Symmetry Medical on the leading edge of the orthopedic industry, providing MAKO and its customers with the assurance of the highest quality for the products surrounding its MAKOplasty(TM) program.”
As the primary supplier of all implants, instruments and products for MAKO, Symmetry Medical will incorporate its Total Solutions(R) offering, an integrated service that encompasses all elements of the orthopedic supply chain, from design and development through final delivery, to ensure MAKO with the highest quality products and prompt distribution channels.
“We are pleased to be working with Symmetry Medical, a company that combines a wealth of industry experience with a vision for growth and innovation that mirrors MAKO’s own ambitions,” commented Maurice R. Ferre, M.D, President and CEO of MAKO Surgical Corp. “In particular, we look forward to incorporating Symmetry Medical’s Total Solutions(R) offering and quickly realizing the benefits that the system provides in terms of product quality, production efficiency and customer delivery.”
About Symmetry Medical Inc.
Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.
About MAKO Surgical Corp
MAKO Surgical Corp. is a privately held, emerging orthopedic medical device company offering MAKOplasty(TM), an innovative, restorative surgical solution that enables orthopedic surgeons to reproducibly and precisely treat patient-specific early to mid stage osteoarthritic knee disease. MAKOplasty is performed using MAKO’s patent-protected, FDA-cleared Haptic Guidance System(TM), a surgeon-interactive haptic robotic platform that utilizes intuitive patient-specific visualization to prepare the knee joint for insertion of MAKO’s resurfacing implants through a keyhole, bone-preserving and tissue-sparing incision. MAKOplasty empowers MAKO’s hospital customers to address the needs of the large and growing, yet underserved population of patients with early to mid stage osteoarthritic knee disease who desire a restoration of lifestyle, pain reduction and a rapid recovery. For more information, please visit www.makosurgical.com.
Forward-Looking Statements
Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be “forward-looking statements” that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual results could differ materially from our current expectations. Certain factors that could cause actual results to differ include: the loss of one or more customers; the development of new products or product innovations by our competitors; product liability; changes in management; changes in conditions effecting the economy, orthopedic device manufacturers or the medical device industry generally; and changes in government regulation of medical devices and third-party reimbursement practices. We refer you to the “Risk Factors” and “Forward Looking Statements” sections in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company’s other filings with the SEC, which are available on the SEC’s Web site at www.sec.gov.
Investors/Media: The Ruth Group Nick Laudico/Jason Rando (646) 536-7030/7025 nlaudico@theruthgroup.comjrando@theruthgroup.com Contact: Symmetry Medical Inc. Fred L. Hite Senior Vice President Chief Financial Officer (574) 371-2218
Symmetry Medical Inc.; MAKO Surgical Corp.
CONTACT: Investors, Media - Nick Laudico, +1-646-536-7030,nlaudico@theruthgroup.com, Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group for Symmetry Medical Inc.and MAKO Surgical Corp.; or Fred L. Hite, Senior Vice President and ChiefFinancial Officer of Symmetry Medical Inc., +1-574-371-2218
Web site: http://www.makosurgical.com/
